Pediatric aspects of HIV1-infection - An overview

Minerva Pediatrica

Volumn 62, Issue 4, 2010, Pages 371-387

  Buchholz, B ^a   Hien, S ^a   Weichert, S ^a   Tenenbaum, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiretroviral therapy; Growth and development; Highly active; HIV1 HIV1; HIV1 infections

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

DREAM; DROWSINESS; EUPHORIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INSOMNIA; LIVER TOXICITY; PATIENT COMPLIANCE; PREGNANCY; PROPHYLAXIS; RASH; REVIEW; SIDE EFFECT; VERTICAL TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL TRIALS AS TOPIC; COUNSELING; DELIVERY, OBSTETRIC; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PATIENT COMPLIANCE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78650749688     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. NAIDS: 2009 global AIDS epidemic update. UNAIDS, Genova 2009.
2. Dabis F, Newell LM, Fowler MG, Read JS. Ghent IAS Working group on HIV1 in Women and Children: prevention of HIV1 transmission through breast feeding: strengthening the research agenda. J Acquir Immune Defic Syndrom 2004;35:167-8.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with Zidovudine treatment. N Engl J Med 1994;331:1173-80.
4. Centers for Disease Control and Prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV infection United States, 1985-2005. MMWR Morb Mortal Wkly Rep 2006;55:592-7.
5. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22:973-81.
6. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005;40:458-65.
7. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dollfus C et al. Mother to child HIV transmission despite antiretroviral therapy in the ARNS French Perinatal Cohort. AIDS 2008;22:289-99.
8. de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008;9:452-502.
9. Carosi G, Nasta P, Fiore S, Matteelli A, Cauda R, Ferrazzi E et al. Italian Working Group for the Women with HIV Management Guidelines. Women facing HIV. Key question on women with HIV infection: Italian consensus workshop. Infection 2009;37:168-78.
10. Buchholz B, Beichert M, Marcus U, Gruben T, Gingelmaier A, Haberl A et al. German-Austrian recommendations for HIV1-therapy in pregnancy - Update 2008. Eur J Med Res 2009; 14:461-79.11
11. Centers of disease control: US Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States - May 24, 2010. [cited 2010 September 91. Available at: http:// www.AIDSinfo.nih.gov
12. Paintsil E, Andiman WA. Update on successes and challenges regarding mother-to-child transmission of HIV. CurrOpin Pediatr 2009;21:94-101.
13. Jasseron C, Mandelbrot L, Tubiana R, Teglas JP, Faye A, Dollfus C et al. ANRS French Perinatal Cohort. Prevention of mother-to-child HIV transmission: similar access for sub-Sahara African immingrants and for French women? AIDS 2008;22:1503-11.
14. Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A et al. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr 2004;36:800-7.
15. Vandermaelen A, Barlow P, Manigart Y, Hainaut M, Goetghebuer T, Levy J et al. Optimal management of HIV-infected women during pregnancy and delivery: an audit of compliance with recommendations. J Womens Health (Larchmt) 2009;18:1881-7.
16. Buchholz B, Dunsch D, Sollinger F, Ndagijimana J., Hornemann F., Vetsi T et al . HIV1-Infektion bei Kindern in Deutschland und Österreich: Häufigkeit und Ursachen der HIV1-Transmission. Eur J Med Res 2003; 8(Suppl.I):12.
17. Report of a consensus workshop, Siena, Italy, January 17-18,1992. Early diagnosis of HIV infection in infants. J Acquir Immune Defic Syndr 1992;5:1169-78.
18. Rossi P, et al. Early diagnosis of HIV infection in infants - Report of a consensus workshop, Siena, Italy, January 17-18, 1992. JAIDS 1992;5:1168-78.
19. Pugatch D. Testing infants for human immunodeficiency virus infection. Pediatr Infect Dis J 2002;21:711-2. (Pubitemid 34761461)
20. Lambert JS, Harris DR, Stiehm ER, Moye J Jr, Fowler MG, Meyer WA 3 et al. Performance characteristics of HIV1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 2003;34:512-9.
21. Centers for Disease Control and Prevention (CDC). Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years United States, 2008. MMWR Recomm Rep 2008;57(RR-10):1-12.
22. Haas J, Geiss M, Bonier T. False-negative polymerase chain reaction-based diagnosis of human immunodeficiency virus type 1 in children infected with HIV strains of African origin. J Infect Dis 1996;174:224-5.
23. Kline NE, Schwarzwald H, Kline MW. False Negative DNA Polymerase Chain Reaction in an infant with subtype C HIV-1 Infection. Pediatr Infect Dis J 2002;21:885-6.
24. Zaman MM, Recco RA, Haag R. Infection with non-B subtype HIV type 1 complicates management of established infection in adult patients and diagnosis of infection in newborn infants. Clin Infect Dis 2002;34:417-8.
25. Obaro SK, Losikoff P, Harwell J, Pugatch D. Failure of serial human immunodeficiency virus type 1 DNA polymerase chain reactions to identify human immunodeficiency virus type 1 clade A/G. Pediatr Infect Dis J 2005;24:183-4. (Pubitemid 40250782)
26. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Recomm Rep 1999;48(RR13):1-27, 29-31.
27. Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43 (No. RR-12):1-10.
28. PENTA Steering Committee, Welch S, Shariand M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection HIV Med 2009;10:591-613.
29. Working group on antiretroviral therapy and medical management of HIV-infected children. 2009 Guidelines for the use of antiretroviral agents in pediatric HIV infection, February 23:1-139. [cited September 2010 9]. Available at: http://aidsinfo.nih.gov/ContentFiles/ PediatricGuidelines.pdf
30. Persaud D, Palumbo P, Ziemniak C, Chen J, Ray SC, Hughes M et al. Pediatric AIDS Clinical Trials Group P1030 Team. Early archiving and predominance of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007;195:1402-10.
31. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. PREDICT-1 Study Team.HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
32. Slyker JA, Lohman-Payne BL, Rowland-Jones SL, Otieno P, Maleche-Obimbo E, Richardson B et al. The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. AIDS 2009;23:117-24.
33. Connell TG, Davies MA Johannisen C, Wood K, Pienaar S, Wilkinson KA et al. Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children. BMC Infect Dis 2010;10:138.
34. Dunn D, HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003;362:1605-11.
35. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J et al. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004. Pediatrics 2007;120:100-9.
36. Gray L, Newell ML, Thome C, Peckham C, Levy J; European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics 2001;108:116-22. (Pubitemid 32592014)
37. Cooper ER, Hanson C, Diaz C, Mendez H, Abboud R, Nugent R et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr 1998;132:808-12.
38. Tardieu M, Le Chenadec J, Persoz A, Meyer L, Blanche S, Mayaux MJ. HIV-1-related encephalopathy in infants compared with children and adults. French Pediatric HIV Infection Study and the SEROCO Group. Neurology 2000;54:1089-95. (Pubitemid 30151850)
39. HIV Paediatric Prognostic Markers Collaborative Study. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005;366:1868-74.
40. Ciuta ST, Boros S, Napoli PA, Pezzotti P, Rezza G. Predictors of survival in children with acquired immunodeficiency syndrome in Italy, 1983 to 1995. AIDS Patient Care STDS 1998;12:629-37.
41. Goetghebuer T, Haelterman E, Le Chenadec J, Dollfus C, Gibb D, Judd A et al. European Infant Collaboration group.Effect of early antiretroviral therapy on the risk of AIDS/death in HIV-infected infants. AIDS 2009;23: 597-604.
42. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al. CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44.
43. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
44. Gibb DM, Castro H, Compagnucci A, Klein N, Lallemant M, Lyall H et al. Paediatric European Network for Treatment of AIDS. Response to planned treatment interruptions in HIV infection varies across childhood. AIDS 2010;24:231-41.
45. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D et al. HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS); Concerted Action on Sero-Conversion to AIDS and Death in Europe (CASCADE) Collaboration. Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis 2008;197:398-404.
46. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIVinfected infants and children. JAMA 1998;279:756-61.
47. Simoni JM, Montgomery A, Martin E, New M, Demas PA, Rana S. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 2007;119:e1371-83.
48. Sadiq ST, Fredericks S, Khoo SH, Rice P, Holt DW. Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. AIDS 2005;19:1716-7.
49. Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML et al. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pretreated vertically HIV-infected children. J Antimicrob Chemother 2008;61:183-90.
50. Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW. Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort. Pediatrics 2006;117:e528-36.
51. Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P et al. Pediatric ACTG 356 Investigators. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Ped Infect Dis J 2001;20:746-51.
52. Wainberg MA, Martinez-Cajas JL. Sequencing of therapy to avoid resistance and the need for new antiretroviral drugs in the treatment of HIV disease. Infect Disord Drug Targets 2009;9:172-90.
53. Green H, Gibb DM, Walker AS, Pillay D, Butler K, Candeias F et al. Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/ lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS 2007;21:947-55.
54. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008;371:1417-26. Erratum in: Lancet. 2008; 372: 292.
55. Puthanakit T, Oberdorfer P, Akarathum N, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006;25:53-8.
56. Brady MT, Oleske JM, Williams PL, Elgie C, Mofenson LM, Dankner WM et al. Pediatric AIDS Clinical Trials Group219/219C Team. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr 2010;53:86-94.
57. Chiappini E, Galli L, Tovo PA, Gabiano C, Lisi C, Gatunara GC et al. Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART. AIDS 2007;21:1607-15.
58. Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R et al. Pediatric AIDS Clincial Trials Group Protocol 219C Team. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Pediatr Adolesc Med 2006;160:778-87.
59. Simoni JM, Amico KR, Smith L, Nelson K. Antiretroviral adherence interventions: translating research findings to the real world clinic. Curr HIV/AIDS Rep 2010;7:44-51.
60. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010;61:169-85.
61. Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J et al. Pediatric AIDS Clinical Trials Group P1045 team. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-72.
62. Kim JY, Zaoutis T, Chu J, Zhao H, Rutstein R. Effects of highly active antiretroviral therapy (HAART) on cholesterol in HIV-1 infected children: a retrospective cohort study. Pharmacoepidemiol Drug Saf 2009;18:589-94.
63. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-51
64. Dzwonek AB, Lawson MS, Cole TJ, Novelli VJ. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. Acquir Immune Defic Syndr 2006;43:121-3.
65. Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J et al. PACTG 1010 Team. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008;122:e129-38.
66. Rosso R, Parodi A, d'Annunzio G, Ginocchio F, Nicolini L, Torrisi C et al. Evaluation of insulin resistance in a cohort of HIV-infected youth. Eur J Endocrinol 2007;157:655-9.
67. Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr 2008;153:491-7.
68. McComsey GA, O'Riordan M, Hazen SL, El-Bejjani D, Bhatt S, Brennan ML et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS 2007;21:921-7.
69. Viganò A, Mora S. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf 2004;3:199-208. (Pubitemid 38765202)
70. Mora S, Zamproni I, Cafarelli L, Giacomet V, Erba P, Zuccotti G, Viganò A. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007;21:1129-35.
71. Smith R, Malee K, Leighty R, Brouwers P, Mellins C, Hittelman J et al. Women and Infants Transmission Study Group. Effects of perinatal HIV infection and associated risk factors on cognitive development among young children. Pediatrics 2006;117:851-62.
72. Mellins CA, Brackis-Cott E, Leu CS, Elkington KS, Doležal C, Wiznia A et al. Rates and types of psychiatric disorders in perinatally human immunodeficiency virusinfected youth and seroreverters. J Child Psychol Psychiatry 2009;50:1131-8.
73. Lee KJ, Lyall EGH, Walker AS. Wide disparitiy in switch to second line therapy in HIV-infected children in CHIPS. 8 International congress on Drug Therapy in HIV Infection. Glasgow, UK. November 2006 (Abstract PL 2.4).
74. Lee KJ, Shingadia D, Pillay D, Walker AS, Riordan A, Menson E et al. Collaborative HIV Paediatric Study Steering Committee. Transient viral load increases in HIV-infected children in the U.K. and Ireland: what do they mean? Antivir Ther 2007;12:949-56.
75. Lesch A, Swartz L, Kagee A, Moodley K, Kafaar Z, Myer L et al Paediatric HIV/AIDS disclosure: towards a developmental and process-oriented approach. AIDS Care 2007;19:811-6.